Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker
Metrics: PDF 557 views | HTML 743 views | ?
Neus Martinez-Bosch1,*, Luis E. Barranco1,2,*, Carlos A. Orozco1,*, Mireia Moreno1, Laura Visa3, Mar Iglesias4, Lucy Oldfield5, John P. Neoptolemos6, William Greenhalf5, Julie Earl7, Alfredo Carrato7, Eithne Costello5 and Pilar Navarro1,8
1Cancer Research Program, IMIM, Hospital del Mar Medical Research Institute, Unidad Asociade CSIC, Barcelona, Spain
2Department of Gastroenterology, Universidad Autonoma de Barcelona, Hospital del Mar, Barcelona, Spain
3Department of Medical Oncology, Hospital del Mar, Barcelona, Spain
4Department of Pathology, Universidad Autonoma de Barcelona, Hospital del Mar, CIBERONC, Barcelona, Spain
5Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK
6Department of General Surgery, University of Heidelberg, Heidelberg, Germany
7Department of Medical Oncology, Ramon y Cajal University Hospital, CIBERONC, IRYCIS, Alcala University, Madrid, Spain
8Institute of Biomedical Research of Barcelona (IIBB-CSIC), Barcelona, Spain
*These authors contributed equally to this work
Pilar Navarro, email: email@example.com
Keywords: galectin-1; pancreatic cancer; chronic pancreatitis; biomarker
Received: August 01, 2018 Accepted: August 16, 2018 Published: August 31, 2018
Pancreatic ductal adenocarcinoma (PDA) is the most frequent type of pancreatic cancer and one of the deadliest diseases overall. New biomarkers are urgently needed to allow early diagnosis, one of the only factors that currently improves prognosis. Here we analyzed whether the detection of circulating galectin-1 (Gal-1), a soluble carbohydrate-binding protein overexpressed in PDA tissue samples, can be used as a biomarker for PDA. Gal-1 levels were determined by ELISA in plasma from healthy controls and patients diagnosed with PDA, using three independent cohorts. Patients with chronic pancreatitis (CP) were also included in the study to analyze the potential of Gal-1 to discriminate between cancer and inflammatory process. Plasma Gal-1 levels were significantly increased in patients with PDA as compared to controls in all three cohorts. Gal-1 sensitivity and specificity values were similar to that of the CA19-9 biomarker (the only FDA-approved blood test biomarker for PDA), and the combination of Gal-1 and CA19-9 significantly improved their individual discriminatory powers. Moreover, high levels of Gal-1 were associated with lower survival in patients with non-resected tumors. Collectively, our data indicate a strong potential of using circulating Gal-1 levels as a biomarker for detection and prognostics of patients with PDA.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.